COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Also, Scripps does not provide COVID-19 tests for asymptomatic patients. See FAQs.

Stroke Prevention in Patients with Atrial Fibrillation

Trial ID:
IRB-21-7811
Douglas Gibson, M.D.
This study will compare if left atrial appendage (LAA) closure with the WATCHMAN FLX Device is a
reasonable alternative to long-term oral anticoagulation (OAC) therapy (blood thinner medication) to prevent strokes in patients with atrial fibrillation (A-Fib).

Inclusion Criteria

Patients must:
  • Be 18 years of age or older
  • Have atrial fibrillation
  • Be suitable for medication regimens
  • Be able and willing to return for required follow-up visits and examinations

Exclusion Criteria

Patients must not:
  • Be allergic to or unable to take oral anticoagulation medication and/or aspirin
  • Have a reversible cause of A-Fib or transient A-Fib
  • Be absent of a LAA or the LAA is surgically ligated

Additional Info

  • All treatments and physician visits during this study will take place at Scripps Memorial Hospital, Anderson Medical Pavilion in La Jolla.
  • Search NCT04394546 at www.clinicaltrials.gov for more information.
  • Study participation will last up to 5 years.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org